Patent application number | Description | Published |
20100160948 | BIOLOGICAL TISSUE GROWTH THROUGH INDUCED TENSILE STRESS - A tissue expansion device implanted in a non-activated state over a region of desired tissue growth. Once implanted and positioned the device is activated creating a supporting structure that creates a convex shaped dome over the underlying tissue. The convex shaped dome formed by the tissue expansion device places a tensile stress against the underlying tissue that promotes tissue growth. Alone or with the introduction of tissue enhancing agents and/or adipose tissue, new tissue within the convex shaped void grows until a balance is achieved eliminating the induced stress. Periodically the tissue expansion devices is again activated and enlarged creating an even larger void. Again, the newly enlarged void places additional tensile stress on the underlying tissue thus repeating the cycle of new tissue growth. Once the desired amount of tissue growth has been achieved the device is deactivated and removed. | 06-24-2010 |
20100161052 | BIOLOGICAL TISSUE GROWTH THROUGH INDUCED TENSILE STRESS - A tissue expansion device implanted in a non-activated state over a region of desired tissue growth. Once implanted and positioned the device is activated creating a supporting structure that creates a convex shaped dome over the underlying tissue. The convex shaped dome formed by the tissue expansion device places a tensile stress against the underlying tissue that promotes tissue growth. Alone or with the introduction of tissue enhancing agents and/or adipose tissue, new tissue within the convex shaped void grows until a balance is achieved eliminating the induced stress. Periodically the tissue expansion devices is again activated and enlarged creating an even larger void. Again, the newly enlarged void places additional tensile stress on the underlying tissue thus repeating the cycle of new tissue growth. Once the desired amount of tissue growth has been achieved the device is deactivated and removed. | 06-24-2010 |
20100168780 | BIOLOGICAL TISSUE GROWTH THROUGH INDUCED TENSILE STRESS - A tissue expansion device implanted in a non-activated state over a region of desired tissue growth. Once implanted and positioned the device is activated creating a supporting structure that creates a convex shaped dome over the underlying tissue. The convex shaped dome formed by the tissue expansion device places a tensile stress against the underlying tissue that promotes tissue growth. Alone or with the introduction of tissue enhancing agents and/or adipose tissue, new tissue within the convex shaped void grows until a balance is achieved eliminating the induced stress. Periodically the tissue expansion devices is again activated and enlarged creating an even larger void. Again, the newly enlarged void places additional tensile stress on the underlying tissue thus repeating the cycle of new tissue growth. Once the desired amount of tissue growth has been achieved the device is deactivated and removed. | 07-01-2010 |
20110317890 | SYSTEM AND METHOD FOR ADVANCED SCANNING AND FOR DEFORMATION SIMULATION OF SURFACES - A system and method for advanced scanning and for simulation of the deformation of surfaces are particularly advantageous for the application of three-dimensional scanning in the medical field. The system and the method allow obtaining digital models of surfaces characterized by an elevated signal-to-noise ratio and by the absence of artefacts due to the movements of the subject during the timing of the scanning. In particular, therefore, the method and system allow obtaining digital models of the surface of particular anatomical areas adapted for the pre-surgery planning, for the estimation and the evaluation of the surgical outcome and for the simulation of the deformation of the bodily surfaces due to predetermined movements performed by the subject. | 12-29-2011 |
20130131655 | BREAST RECONSTRUCTION OR AUGMENTATION USING COMPUTER-MODELED DEPOSITION OF PROCESSED ADIPOSE TISSUE - A tissue transfer method for reconstruction and augmentation of soft tissue. The method includes harvesting adipose tissue from a patient. The harvested tissue is processed via centrifugation to isolate a purified subset of the adipose tissue including separating and removing a substantial amount of triglycerides from the harvested adipose tissue. The centrifugation may be performed to cause separation of water from the purified adipose tissue and to cause separation of oil from mature adipocytes. Specifically, the spin rates may be selected to be high enough to cause lesions in the mature adipocytes that results in the release of the oil. The method continues with implanting the purified adipose tissue into the patient at a breast or other area identified for reconstruction or augmentation. The implanting is performed based on an injection pathway model that defines injection point locations and a number of injection pathway directions from each point. | 05-23-2013 |
Patent application number | Description | Published |
20110144120 | PHENYL-ALKYL PIPERAZINES HAVING TNF-MODULATING ACTIVITY, PREPARATION METHOD, AND THERAPEUTIC USE THEREOF - The present invention relates to phenyl-alkyl piperazines of formula (I): | 06-16-2011 |
20110144122 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): | 06-16-2011 |
20120245149 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyI)-1-alkanone derivatives of formula (I): | 09-27-2012 |
20120245150 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-tetrahydropyridine)(piperazinyl)-1-alkanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alkanone derivatives of formula (I): | 09-27-2012 |
20120289518 | DERIVATIVES OF 2-OXOALKYL-1-PIPERAZIN-2-ONE, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME - The present invention relates to derivatives of 4-{2-[phenyl-3,6-dihydropyridin-1-yl]-2-oxoalkyl}-1-piperazin-2-one and 4-{2-[phenyl-2,5-dihydropyrrol-1-yl]-2-oxoalkyl}-1-piperazin-2-one having general formula (I): | 11-15-2012 |
20130303520 | NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-tetrahydropyridine)(piperazinyl)-1-alkanone and (heterocycle-dihydropyrrolidine)(piperazinyl)-1-alkanone derivatives of formula (I): | 11-14-2013 |
20140038946 | NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS - The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivatives of formula (I): | 02-06-2014 |
Patent application number | Description | Published |
20090258837 | Analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 10-15-2009 |
20100323980 | Improvements to analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 12-23-2010 |
20110218164 | THERAPEUTIC, DIETARY OR COSMETIC USE OF COMPOUNDS WITH SPECIFIC ANTI-APOPTOTIC ACTIVITY TOWARD CASPASE-3, AND COMPOSITIONS CONTAINING THESE COMPOUNDS - This invention regards the use of zeaxanthin and/or rutin, as such or further combined with spermidine, as the active principle in a pharmaceutical, dietary, or cosmetic composition, acting to inhibit caspase-3 and therefore to control apoptosis by preventing programmed cell death. | 09-08-2011 |
20110224298 | DIENE COMPOUNDS FOR USE IN HUMAN EPIDERMAL CELL REPAIR AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - The present invention relates to a novel use of compounds having the general formula (I): | 09-15-2011 |
Patent application number | Description | Published |
20090048343 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 02-19-2009 |
20090118357 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field - Therefore the present invention relates specifically to the compounds of general formula (I), in which R | 05-07-2009 |
20110039808 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor - There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group. | 02-17-2011 |
20110218245 | USE OF COMPOUNDS TO INHIBIT 5A-REDUCTASE ENZYME ACTIVITY, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - The object of the present invention is the use of compounds designed to inhibit the activity of the enzyme 5α-reductase. This is a novel use of compounds of general formula (I): | 09-08-2011 |
20120121705 | Pharmaceutical Or Cosmetic Or Dietetic Composition Suitable For Promoting A Hair Pigmentation Effect - The invention relates to the use of spermidine or a pharmaceutically acceptable derivative thereof as the active principle in a pharmaceutical, cosmetic or dietetic composition. The composition is used for promoting pigmentation of the hair, particularly the shaft of the hair. The invention also relates to the composition which promotes this pigmentation effect, the composition containing spermidine or a derivative thereof (such as a salt) as an active principle and is intended for topical or oral administration. | 05-17-2012 |
20120316230 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds of formula (I), where R | 12-13-2012 |
20130005813 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 01-03-2013 |
20130102712 | ADDUCTS WITH PERFLUOROPOLYETHER PHOSPHATE AND USES THEREOF - The present invention relates, in one aspect, to an adduct of formula O-PF-A, in which O is an oil; PF is a perfluoropolyether phosphate (PFPE phosphate); A is at least one substance selected from: (X) a water-soluble polyhydroxylated substance and (Y) a water-insoluble inorganic substance and to topical applications thereof in particular in the cosmetic and pharmaceutical field. | 04-25-2013 |
20130121916 | Compositions for Colon Lavage and Methods of Making and Using Same - Disclosed herein are compositions that include polyethylene glycol; alkali metal sulfate; electrolytes selected from the group consisting of sodium bicarbonate, sodium chloride, and potassium chloride or a mixture thereof; and a gastro-protected dye composition comprising a gastro-protectant and a dye suitable for use in an internal colon examination procedure. Also provided herein are sachets, and containers, e.g. sachets that include disclosed compositions; kits for colon cleansing, and aqueous solutions suitable for colon cleansing. | 05-16-2013 |
20130150443 | DIENE COMPOUNDS FOR USE IN HUMAN EPIDERMAL CELL REPAIR, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - The present invention relates to a novel use of compounds having the general formula (I): | 06-13-2013 |
20140030207 | SYSTEM FOR PROLONGED RELEASE OF COSMETIC AGENTS - The present invention relates to a system for the release of cosmetic agents comprising at least one phospholipid, hyaluronic acid or derivatives thereof and a cationic polyurethane derivative. The system of the invention may be used in the formulation of cosmetic preparations for obtaining the protracted release of cosmetic agents or active substances to the epidermis or the keratinic structures of the human body, with a simultaneous reduction in the frequency of application. | 01-30-2014 |
20150045436 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 02-12-2015 |
20150051285 | Alkylamido Compounds and Uses Thereof - Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same. | 02-19-2015 |
20150087678 | METHODS OF TREATING LACTOSE INTOLERANCE - Disclosed herein are methods for treating lactose intolerance, including compounds that may be specific or modulate PPARγ receptors. | 03-26-2015 |
20150087708 | METHODS OF TREATING FIBROSIS - The present disclosure is directed in part to methods of treating fibrosis, e.g., hepatic fibrosis and/or intestinal fibrosis, comprising administering to a patient in need thereof an effective amount of a disclosed compound. | 03-26-2015 |
20150148418 | Methods of Treating Hair Related Conditions - Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors. | 05-28-2015 |
20150202132 | PHARMACEUTICAL OR COSMETIC COMPOSITION FOR TREATING ALOPECIA - The present invention relates to a cosmetic or pharmaceutical composition for treating alopecia, and in general for counteracting excessive hair loss, comprising as an active ingredient a compound of formula (I) R—N | 07-23-2015 |
20150250749 | METHODS OF TREATING HAIR RELATED CONDITIONS - Provided herein are methods for enhancing epidermal regeneration in a patient in need thereof, comprising topically administering to said patient a pharmaceutically acceptable composition comprising N-acetyl-3-(4-aminophenyl)-2-methoxypropionic acid or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient. For example, provided are methods for treating or ameliorating cicatricial alopecia, comprising topically administering to a patient in need thereof a pharmaceutically acceptable composition comprising the disclosed compounds. Also provided are methods for protecting hair follicle progenitor cells and compositions comprising same using the disclosed compounds. | 09-10-2015 |
20150265514 | METHODS OF INHIBITING HAIR GROWTH - Provided herein are methods for reducing mammalian hair growth using the disclosed compounds. Also provided herein are methods of inhibiting hair growth after hair removal of an area of mammalian skin of a mammal using the disclosed compounds. | 09-24-2015 |
20150265562 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 09-24-2015 |
20150265563 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 09-24-2015 |
20150366770 | COMPOSITION FOR COSMETIC USE SUITABLE TO PRODUCE A PIGMENTATION EFFECT ON HAIR - The invention concerns the use of compounds with formula (I) R—N1-spermidine, or 1,4-butandiamin,N-(3-amino propyl)-N1-R, (I) H | 12-24-2015 |
20160030365 | PHARMACEUTICAL OR COSMETIC COMPOSITION SUITABLE TO PRESERVE EPITHELIAL STEM CELLS - The invention concerns the use of compounds of formula (I) R-N | 02-04-2016 |
20160030500 | FLAVONOID-BASED COMPOSITION FOR PHARMACEUTICAL, NUTRITIONAL OR COSMETIC USE HAVING POTENTIATED ANTIOXIDANT ACTION - The invention relates to a composition for pharmaceutical or nutritional or cosmetic use, formulated for oral or topical use and possessing antioxidant activity against free radicals, comprising: a) a | 02-04-2016 |
20160067161 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR RESISTING SKIN AGEING THROUGH AN ANTI-INFLAMMATORY ACTION - The invention relates to the use of compounds of formula (I) R—N | 03-10-2016 |
Patent application number | Description | Published |
20110288058 | Methods for Preventing or Reducing Colon Carcinogenesis - The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient in need thereof an antioxidant effective amount of a compound represented by formula I, IIa or IIb as disclosed herein. | 11-24-2011 |
20110288177 | Methods for Preventing or Reducing Colon Carcinogenesis - The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising a chemopreventive agent disclosed herein. | 11-24-2011 |
20120015033 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 01-19-2012 |
20120094948 | Analogous Compounds of 6-Thioguanosine Triphosphate, their use in Medical Fields and Processes for their Preparation - The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general formula -(Int) | 04-19-2012 |
20150125523 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 05-07-2015 |
20150232854 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 08-20-2015 |